WO2025219945 - PURIFICATION OF RIFABUTIN FORMULATIONS
National phase entry is expected:
Publication Number
WO/2025/219945
Publication Date
23.10.2025
International Application No.
PCT/IB2025/054072
International Filing Date
17.04.2025
Title **
[English]
PURIFICATION OF RIFABUTIN FORMULATIONS
[French]
PURIFICATION DE FORMULATIONS DE RIFABUTINE
Applicants **
BIOVERSYS AG
Inventors
SCHILL, Julian
JÄGER, Jürgen
GITZINGER, Marc
DALE, Glenn E.
Priority Data
63/635,136
17.04.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2139 | |
| EPO | Filing, Examination, Granting | 10199 | |
| Japan | Filing, Examination, Granting | 2294 | |
| South Korea | Filing, Examination, Granting | 2297 | |
| USA | Filing, Examination, Granting | 5340 |
Total:
22,269
Contact Us
Abstract[English]
The invention provides compositions and methods of creating a rifabutin powder suitable for IV formulation preparation.[French]
L'invention concerne des compositions et des procédés pour produire une poudre de rifabutine appropriée pour la préparation de formulation IV.